Matinas Biopharma (NYSEAMERICAN:MTNB) Stock Price Down 0.4% – Time to Sell?

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNBGet Free Report)’s stock price dropped 0.4% during trading on Friday . The company traded as low as $0.7655 and last traded at $0.79. Approximately 19,355 shares traded hands during mid-day trading, a decline of 37% from the average daily volume of 30,777 shares. The stock had previously closed at $0.7929.

Matinas Biopharma Stock Down 0.4%

The company’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.29. The company has a market cap of $5.06 million, a price-to-earnings ratio of -0.23 and a beta of 1.32.

Matinas Biopharma (NYSEAMERICAN:MTNBGet Free Report) last announced its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter.

Matinas Biopharma Company Profile

(Get Free Report)

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.

Featured Articles

Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.